Literature DB >> 3315623

Intermittent claudication. An update on management.

P A Blombery1.   

Abstract

The mainstay of treatment for claudication is reversal of risk factors, especially smoking, and the use of antiplatelet drugs and possibly pentoxifylline. A major factor in the long term management is atherosclerotic involvement in other parts of the circulation resulting in a shortened life span. Treatment should be directed at the disease in general, rather than in the legs alone. Patients disabled by claudication may gain symptomatic relief with relatively low risk using balloon angioplasty or vascular reconstructive procedures.

Entities:  

Mesh:

Year:  1987        PMID: 3315623     DOI: 10.2165/00003495-198734030-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

1.  Intermittent claudication: its natural course.

Authors:  A M Imparato; G E Kim; T Davidson; J G Crowley
Journal:  Surgery       Date:  1975-12       Impact factor: 3.982

2.  Fate in intermittent claudication: outcome and risk factors.

Authors:  R Jelnes; O Gaardsting; K Hougaard Jensen; N Baekgaard; K H Tønnesen; T Schroeder
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

3.  Results of ankle ststolic pressure measurements in patients with intermittent claudication being treated with clofibrate.

Authors:  J C Postlethwaite; J A Dormandy
Journal:  Ann Surg       Date:  1975-06       Impact factor: 12.969

4.  Differential inhibition of prostacyclin production and platelet aggregation by aspirin.

Authors:  G Masotti; G Galanti; L Poggesi; R Abbate; G G Neri Serneri
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

5.  Failure of autogenous reversed saphenous vein femoropopliteal grafting: pathophysiology and prevention.

Authors:  L K LiCalzi; H C Stansel
Journal:  Surgery       Date:  1982-03       Impact factor: 3.982

6.  Comparison of above-knee and below-knee anastomosis in femoropopliteal bypass grafts.

Authors:  D C Brewster; A J LaSalle; R C Darling
Journal:  Arch Surg       Date:  1981-08

7.  Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.

Authors:  J De Cree; J Leempoels; H Geukens; H Verhaegen
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

8.  Intermittent claudication: a double-blind crossover trial of pentoxifylline.

Authors:  A S Gallus; F Gleadow; P Dupont; J Walsh; A A Morley; A Wenzel; M Alderman; D Chivers
Journal:  Aust N Z J Med       Date:  1985-08

9.  Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication.

Authors:  R S Smith; D J Warren
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jan-Feb       Impact factor: 3.105

Review 10.  Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects.

Authors:  D M Aviado; J M Porter
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

View more
  2 in total

Review 1.  Pharmacological approaches to the treatment of intermittent claudication.

Authors:  E G Bevan; P C Waller; L E Ramsay
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

2. 

Authors:  C Diehm; H Heidrich; F Spengel; K L Schulte; W Theiss
Journal:  Internist (Berl)       Date:  2000-11       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.